Revive Therapeutics Ltd. (RVVTF)
| Previous Close | 0.3070 |
| Open | 0.3044 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.2848 - 0.3054 |
| 52 Week Range | 0.1200 - 0.4830 |
| Volume | |
| Avg. Volume | 445,693 |
| Market Cap | 108.757M |
| Beta (5Y Monthly) | -0.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
TORONTO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and a
- GlobeNewswire
Revive Therapeutics Advances Inflammatory Liver Disorders Programs for Autoimmune Hepatitis and Liver Transplantation
WHO reports 650 probable cases of acute hepatitis of unknown aetiology in children from 33 countries Company received FDA orphan drug designation for Bucillamine in the prevention of ischemia-reperfusion injury during liver transplantation and Cannabidiol for autoimmune hepatitis Company intends to move its head office to the US to better support growing drug programs with Bucillamine, Cannabidiol, and Psilocybin TORONTO, May 31, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the
- GlobeNewswire
PharmaTher Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Recent Business Highlights and Update
Nearly $12 million in cash and investment Fully funded for the Company’s development programs, including ketamine injection and infusion product, ketamine microneedle patch and ketamine wearable pump device for mental health, neurological, and pain disorders Seeking FDA approval for KETARX™ (ketamine injection and infusion product) for anesthesia and procedural sedation TORONTO, April 25, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM)
